RESUMO
ObjectiveTo observe the effects of Internet plus continuous rehabilitation nursing on older patients after lumbar fusion. MethodsFrom January, 2018 to August, 2021, 157 older patients after transforaminal lumbar interbody fusion (TLIF) in Department of Orthopedics, Chongqing General Hospital were retrospectively studied. A total of 66 patients accepting routine continuous rehabilitation nursing care were as control group, and 91 patients accepting internet plus continuous rehabilitation nursing care were as intervention group. They were assessed with Visual Analog Scale for pain (VAS), Oswestry Disability Index (ODI), Huaxi Emotional-distress Index (HEI) and Adult Health Self-management Skill Rating Scale (AHSMSRS) before, and one and three months after intervention. The compliance and nursing satisfaction were investigated with self-made questionnaire three months after intervention, and the postoperative complications were recorded. ResultsA total of 148 patients finished follow-up of three months, including 61 patients for the control group and 87 patients for the intervention group. The VAS, ODI, HEI and AHSMSRS scores improved in both groups one and three months after intervention (F > 85.4, P < 0.001), and improved more in the intervention group than in the control group (|t| > 3.645, P < 0.001). Both the compliance and nursing satisfaction were better in the intervention group than in the control group (χ2 > 5.478, P < 0.05), and no postoperative complication was observed in both groups. ConclusionInternet plus continuous rehabilitation nursing can promote the recovery of function, pain and psychological emotion, ability of self-management, compliance, and nursing satisfaction.
RESUMO
<p><b>OBJECTIVE</b>To investigate whether xuezhikang has additional beneficial effect on lipid peroxidation, myocardial fibrosis, inflammation and blood pressure control in hypertensive patients without sever hyperlipidemia treated with extended-released nifedipine.</p><p><b>METHODS</b>This is a randomized, single-blind, placebo-controlled study, 100 patients with primary hypertension (HT) and normal or lightly elevated cholesterol level were randomized to receive placebo (n=49) or xuezhikang (1200 mg/d, n=51) for 24 weeks on top of extended-released nifedipine (20 mg, bid), 30 healthy volunteers served as controls. Plasma was obtained at baseline and 24 weeks after therapy. Lipids, C-reactive protein (CRP), malondialdehyde (MDA), superoxide dismutase photo-inhibition rate (SOD-PR) and type I collagen carboxypropeptide (PIP) were measured.</p><p><b>RESULTS</b>Normal blood pressure (<140/90 mm Hg) was found in 49 out of 51 xuezhikang treated patients and in 40 out of 49 placebo treated patients (P<0.01) after 24 weeks therapy. Plasma CRP, MDA, SOD-PR and PIP were significantly higher in HT patients than those in normal controls. Plasma CRP, MDA, PIP and SOD-PR were significantly decreased in xuezhikang group while remained unchanged in placebo group after 24 weeks treatment.</p><p><b>CONCLUSION</b>In patients with primary hypertension without severe hyperlipidemia treated with nifedipine, xuezhikang treatment exerts additional beneficial effects including better blood pressure control, endothelial function improvement, lipid oxidation loading attenuation and anti-inflammation.</p>